IL313420A - Compound, Aldehyde Dehydrogenase 2 Activator, Pharmaceutical Preparation and Treatment and/or Prophylactic Drug - Google Patents
Compound, Aldehyde Dehydrogenase 2 Activator, Pharmaceutical Preparation and Treatment and/or Prophylactic DrugInfo
- Publication number
- IL313420A IL313420A IL313420A IL31342024A IL313420A IL 313420 A IL313420 A IL 313420A IL 313420 A IL313420 A IL 313420A IL 31342024 A IL31342024 A IL 31342024A IL 313420 A IL313420 A IL 313420A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- mmol
- prodrug
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022070667 | 2022-04-22 | ||
| PCT/JP2023/015870 WO2023204292A1 (ja) | 2022-04-22 | 2023-04-21 | 化合物、アルデヒドデヒドロゲナーゼ２活性化剤、医薬組成物、並びに治療及び／又は予防薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL313420A true IL313420A (en) | 2024-08-01 |
Family
ID=88419993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL313420A IL313420A (en) | 2022-04-22 | 2023-04-21 | Compound, Aldehyde Dehydrogenase 2 Activator, Pharmaceutical Preparation and Treatment and/or Prophylactic Drug |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250084036A1 (https=) |
| EP (1) | EP4512468A4 (https=) |
| JP (1) | JPWO2023204292A1 (https=) |
| KR (1) | KR20250005979A (https=) |
| CN (1) | CN118591526A (https=) |
| AR (1) | AR129100A1 (https=) |
| AU (1) | AU2023257780A1 (https=) |
| CA (1) | CA3243949A1 (https=) |
| IL (1) | IL313420A (https=) |
| MX (1) | MX2024007847A (https=) |
| TW (1) | TW202345820A (https=) |
| WO (1) | WO2023204292A1 (https=) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7875411B2 (en) | 2006-10-30 | 2011-01-25 | Xerox Corporation | Photoreceptor containing substituted biphenyl diamine and method of forming same |
| US20110105602A2 (en) | 2007-03-08 | 2011-05-05 | Daria Mochly-Rosen | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof |
| JP6160114B2 (ja) | 2013-02-20 | 2017-07-12 | 富士ゼロックス株式会社 | 画像形成装置 |
| WO2014160185A2 (en) | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
| JP5794369B2 (ja) | 2013-11-26 | 2015-10-14 | 大日本印刷株式会社 | ウィンドウフィルム |
| HUE051255T2 (hu) | 2014-02-19 | 2021-03-01 | Aviv Therapeutics Inc | Mitokondriális aldehid dehidrogenáz 2 (ALDH2) kötõ policiklusos amidok és alkalmazásuk rák kezelésére |
| KR20200115474A (ko) | 2018-01-31 | 2020-10-07 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Aldh2 활성화제 |
| JP2019151241A (ja) | 2018-03-05 | 2019-09-12 | トヨタ紡織株式会社 | 乗物用シート |
| CN108864034A (zh) | 2018-06-04 | 2018-11-23 | 中国人民解放军第二军医大学 | 酰胺类醛脱氢酶激动剂、其合成方法及用途 |
| WO2022092310A1 (ja) * | 2020-11-02 | 2022-05-05 | 株式会社アークメディスン | 化合物、アルデヒドデヒドロゲナーゼ２活性化剤、医薬組成物、並びに治療及び／又は予防薬 |
-
2023
- 2023-04-21 JP JP2024516325A patent/JPWO2023204292A1/ja active Pending
- 2023-04-21 CN CN202380018326.4A patent/CN118591526A/zh active Pending
- 2023-04-21 TW TW112114876A patent/TW202345820A/zh unknown
- 2023-04-21 EP EP23791940.2A patent/EP4512468A4/en active Pending
- 2023-04-21 KR KR1020247030355A patent/KR20250005979A/ko active Pending
- 2023-04-21 CA CA3243949A patent/CA3243949A1/en active Pending
- 2023-04-21 MX MX2024007847A patent/MX2024007847A/es unknown
- 2023-04-21 IL IL313420A patent/IL313420A/en unknown
- 2023-04-21 WO PCT/JP2023/015870 patent/WO2023204292A1/ja not_active Ceased
- 2023-04-21 US US18/728,707 patent/US20250084036A1/en active Pending
- 2023-04-21 AU AU2023257780A patent/AU2023257780A1/en active Pending
- 2023-04-21 AR ARP230100953A patent/AR129100A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023204292A1 (ja) | 2023-10-26 |
| US20250084036A1 (en) | 2025-03-13 |
| KR20250005979A (ko) | 2025-01-10 |
| EP4512468A4 (en) | 2026-04-08 |
| MX2024007847A (es) | 2024-07-09 |
| AR129100A1 (es) | 2024-07-17 |
| CA3243949A1 (en) | 2025-06-17 |
| JPWO2023204292A1 (https=) | 2023-10-26 |
| EP4512468A1 (en) | 2025-02-26 |
| AU2023257780A1 (en) | 2024-07-04 |
| TW202345820A (zh) | 2023-12-01 |
| CN118591526A (zh) | 2024-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9206128B2 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| JP7099672B2 (ja) | 医薬化合物 | |
| IL298753A (en) | A pentavalent heteroaromatic imidazole compound and its use | |
| IL310699B1 (en) | Thr-beta receptor agonist compound and preparation method and use thereof | |
| US20120071475A1 (en) | Urea derivatives having pi3k-inhibiting activity | |
| IL263493A (en) | Modulating compounds (fxr (nr1h4) | |
| IL266126A (en) | Pyridone compound as a c – met inhibitor | |
| IL258486A (en) | Compounds, compositions, and methods for modulating cftr | |
| IL284591B1 (en) | Fxr (nr1h4) modulating compounds | |
| JP2024522009A5 (https=) | ||
| IL303209A (en) | A heteroaryl carboxamide compound | |
| IL278281B2 (en) | Crystalline form of C–MET inhibitor and its salt form and method for preparing them | |
| NZ579355A (en) | 2-(Aryl)-4-oxo-quinazoline derivatives | |
| IL268010A (en) | Pyrimidine compound and its pharmaceutical use | |
| IL302378A (en) | Compound, Aldehyde Dehydrogenase 2 Activator, Pharmaceutical Preparation and Treatment and/or Prophylactic Drug | |
| IL296007A (en) | Synthesis of a new EP4 antibody and use for cancer and inflammation | |
| IL283182B1 (en) | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | |
| IL281391B1 (en) | Imidazopyridinone compound | |
| NZ560805A (en) | Isoxazoline derivative and novel process for its preparation | |
| IL258952A (en) | Pyranodipyridine compound | |
| IL291114B2 (en) | Pyrimidine compound and method for preparing same | |
| IL303307A (en) | Tetrahydroquinoline derivative and its medical use | |
| IL296532A (en) | Crystal forms of farnesoid x receptor agonist | |
| IL319273A (en) | A series of bridged nitrogen-containing heterocyclic compounds and a method for their preparation | |
| IL313420A (en) | Compound, Aldehyde Dehydrogenase 2 Activator, Pharmaceutical Preparation and Treatment and/or Prophylactic Drug |